Human epidermal growth factor receptor negative

1 trials 1 recruiting MedDRA PT
1 Registered trials
1 Recruiting
1 Unique sponsors
2 Unique IMPs
1 Commercial trials
Drug classes (ATC)
L Oncology (ATC L) 1
Mechanism of action (INN-stem analysis)
Antibody-drug conjugate (ADC) 1 substance
Checkpoint inhibitor (PD-1) 1 substance
Phase II: 1

Filter these 1 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 1 trials

Phase II

1 trial
  • Merck Sharp & Dohme LLC Commercial
    PATRITUMAB DERUXTECAN; PEMBROLIZUMAB
    2024-514376-40-00 1 country 2025 n=10
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Merck Sharp & Dohme LLC Commercial 1 Phase II 1
New trials by year
2025
1
← All indication landscapes